Clinical Trial Update: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) [Phase 3]

View source ↗

Summary

Phase 3 study comparing BL-B01D1 to chemotherapy of physician's choice in unresectable locally advanced, recurrent, or metastatic HR-positive, HER2-negative bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• BL-B01D1
• Chemotherapy (physician's choice)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: HR+HER2- Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING